nanoparticles Archives - Halberd Corporation

Halberd Corporation Reports Successful Conjugation of Metallic Particles & SARS-CoV-2 Proprietary Monoclonal Antibody

Jackson Center, PA, May 17, 2021 – Halberd Corporation (OTC-PINK: "HALB") announces the successful conjugation of gold-coated iron nanoparticles with Halberd’s patent-pending monoclonal antibody against the SARS-CoV-2 spike protein. This milestone paves the way for testing to proceed on the elimination of disease through the application of extracorporeal radio frequency waves or laser emissive energy ...

Halberd Corporation’s Scientific Breakthrough: Conjugating Metallic Particles to SARS-CoV-2 and E. Coli Antigens

By Admin|2021-03-29T20:24:19-04:00March 30th, 2021|Featured, Investor News, News, Uncategorized|0 Comments

Paves Way for Disease Elimination by Radio Frequency Waves Jackson Center, PA, March 30, 2021 – Halberd Corporation (OTC-PINK: "HALB") has successfully conjugated (joined) metallic nanoparticles with its patent-pending SARS-CoV-2 antibody, while still maintaining the antibody’s antigen-neutralizing properties. This was a key scientific hurdle to overcome in implementing its patent-pending extracorporeal disease eradication methodology through ...